Nelly A. Kalinina

Learn More
Respiratory viral infections constitute the most frequent reason for medical consultations in the World. They can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions such as pneumonia. In particular, in serious cases influenza A leads to pneumonia, which is(More)
Light- and fluorescence-microscopy examinations of 186 placentas were carried out, with concurrent determination of placental interferon, isolation of influenza virus, and serologic tests of maternal and fetal blood, and amniotic fluid. In 32 of the cases, placentitis caused by serotype A or B of influenza virus was present, characterized by hyperplasia and(More)
The protective activity of Ingavirin against experimental infection caused by influenza B virus was studied on albino mice vs. Arbidol. Oral use of Ingavirin was shown to decrease the infectious titers of the virus in the animal lung tissue, to normalize the body weight dynamics, to lower the mortality and to increase the average lifespan vs. the(More)
Despite obvious success in the vaccine development and chemotherapy of influenza, it remains a poorly controlled infection leading to emergence of new pandemic variants of the virus with high morbidity and mortality. We investigated the protective activity of Ingavirin against the lethal influenza A (H1N1) 2009 virus infection on albino mice. Oral use of(More)
A convenient procedure for the isolation of specificEcoRI-fragments ofE. coli genome and their amplification on Km-resistance plasmid vector CK Δ11 is described. The hybrid molecules were constructedin vitro usingEcoRI-digestion, followed by ligation. Then appropriatedE. coli strain was transformed with ligated DNA mixture and hybrid plasmids CK Δ11-arg +,(More)
W. Voelter, G. Jung, A. Bre i tmaier , et al., Z. Naturforsch. , 266, 213 1971). S. J. Pasar ibu, Aust. J. Chem., 30, 2533 (1977). E. P. Krysin, V. N. Karel ' ski i , et al., Khim. Pr [ r . Soedin., No. 4, 482 (1978). Belgium patent No. 659048 (1965); Chem. Abstr . , 64, 2161 (t966). Swiss Patent No. 459252 (1968). E. P. Krysin, V. N. Karel ' sk i i , et(More)
The results obtained demonstrate that the two agents differ in principle in their mode of action on the heat exchange. Bacterial pyrogens, in minimal doses, cause an active neurogenic increase in body temperaturea pyrexialreaction-whereas DNP, which is mainly, (if not entirely) a peripheraUy acting agent, even in relatively large doses, has practicaIly no(More)